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Abstract 
Ascites, dilutional hyponatremia and hepatorenal syndrome are three clinical manifestations of the same 
physiopathological disorder: cirrhotic portal hypertension, hyperproduction of nitric oxide, arterial vasodilation with reduction of 
efficient arterial volume, which have as consequences renal vasoconstriction, sympathetic stimulation, the stimulation of renin-
angiotensin-aldosteron system and of vasopressin secretion. In dilutional hyponatremia, the selective receptor V2 (vasopressin 1) 
antagonists may be efficient according to Spanish and American specialists and also according to personal experience [6,9]. 
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Abbreviations: Ly = lymphatic hyperproduction; Alb = hypoalbuminaemia; NO = nitric oxide; Sy = sympathetic (nervous) 
system; HRS = hepatorenal syndrome. 
asd
In portal hypertension (PHT) there is a functional 
hemodynamic intrarenal disorder and a strong stimulation 
of renin-angiotensin-aldosterone system (RAAS) and also 
a high level of circulating vasopressin. PHT is the cause 
of local hyperproduction of nitric oxide (NO) and of other 
substances (adrenomedulin, glucagon) which are all 
strong arterial vasodilators. 
This arterial vasodilation is dominant in 
splanchnic territory. The arterial vasodilation explains the 
reduction of the efficient arterial volume (EAV) and the 
tendency of the arterial pressure to drop. The reduced 
EAV strongly stimulates volume receptors with a strong 
sympathetic stimulation and also the stimulation of RAAS 
of vasopressin production and with renal cortical 
vasoconstriction [1-5,7]. 
These mechanisms have initially had an 
adaptative function in order to reestablish the EAV and 
the arterial pressure: the rise in plasma volume secondary 
to renal retention of H2O and Na+, systemic arterial 
vasoconstriction (except for splanchnic arteries) 
secondary to the stimulation of V1 vascular receptors by 
vasopressin, the rise in cardiac output [10]. 
In more advanced stages of cirrhosis, the same 
mechanisms, initially adaptative, become causes of 
pathology: 
1. Ascites as a consequence of an excessive 
renal H2O and Na+ retention (↑RAAS). 
2. Dilutional hyponatraemia appears as a 
consequence of the V2 renal tubular receptors stimulation 
by vasopressin with renal selective retro resorption of 
water. Selective vasopressin 1(V1) receptor antagonists 
are efficient in many of these cases [6,7,9]. 
3. Hepatorenal syndrome which follows an 
extreme renal vasoconstriction. 
In these later stages, EAV and arterial pressure 
are reduced and natriuria drops dramatically. The water 
and Na+ renal retention are predominantly distributed in 
the venous visceral territory (“visceral sequestration”) and 
a normal EAV cannot be reestablished. Visceral capillary 
pressure raises which, in the presence of 
hypoalbuminaemia, results in peritoneal transudation of 
fluid and in hyperproduction of visceral lymph, resulting in 
ascites formation. 
Renal hemodynamic disturbance begins before 
any ascites exists (Table 1). In this preascitic stage, renal 
sodium excretion is already impaired, but can be proved 
only when sodium intake is higher than normal. Renal 
vasoconstriction is not very strong and can be 
counterbalanced by the renal vasodilators mechanisms 
(prostaglandins and others). In the presence of ascites, 
renal vasoconstriction is more important and the Na+ renal 
excretion is impaired. In refractory ascites, mortality is 
higher and a hepatorenal syndrome (type II) follows in 
40% of the cases. 
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  Tabel 1 Progressive alteration of creatinine and sodium excretion in portal hypertension [8]. 
 
 
Stage  Creatinine 
(serum) 
Renal 
vasoconstrictor 
mechanisms(+)ver
sus vasodilating 
mechanisms(-) 
Sodium excretion is impaired (+) or normal (N) 
↑ Na+ 
Intake 
Normal 
Na+ intake 
↓ Na+ 
Intake  
↓ Na+ Intake  
and 
diuretics 
Preascitic  N  +/--  +  N  N  N 
Moderate ascites  N  +/-  +  +  +/-  N 
Important ascites  N  ++/-  +  +  +  N 
Refractory ascites  1,2 –1,4 mg/dl 
40% HRS II  +++/-  +  +  +  + 
Hepatorenal syndrome  >1,5 mg/dl  +++  +  +  +  + 
 
A refractory ascites appears in spontaneous 
bacterial peritonitis, dilutional hyponatremia and HRS type 
II. In spontaneous bacterial peritonitis, aerobic Gram- 
negative bacteria are translocated from the intestine and 
can produce an inflammatory peritoneal response. They 
can also activate monocytes with the production of 
proinflamatory cytokines and supplementary NO, which 
increase arterial vasodilation. There is also an 
overexpression of Toll-like receptors and activation of NF-
κB (nuclear factor κB) [10]. In these circumstances, the 
possibility of HRS occurrence increases. In dilutional 
hyponatraemia, V2 receptor antagonists obtained by 
cloning V2 receptors are efficient. A diuresis of 3-9 l/24h 
and 3-5 l after a single dose can be obtained with 
Satavaptan, urinary Na rises, ascites and edema are 
reduced [6,9]. These drugs also prevent the recurrences 
of ascites, diuretic induced hyponatraemia and may be 
useful in refractory cardiac insufficiency. V2 receptor 
antagonists prevent hepatic encephalopathy after hepatic 
transplantation. 
When renal vasoconstriction is very strong and 
renal vasodilator mechanisms are overwhelmed by 
vasoconstrictor ones, hepatorenal syndrome (type I, 
which presents as an acute renal failure, and type II, 
which presents as a refractory ascites) [8]. When a HRS 
appears, some supplementary vasoconstrictors become 
active (Table 2): the rise in plasmatic level of endothelins 
(as an effect of endotoxinaemia) and a significant rise of 
the angiotensin II, an intrarenal invasion of 
vasoconstrictors, as a consequence of a raised 
production of tromboxans, leukotriens and adenosine, 
and, also a reduced production of intrarenal vasodilators 
such as some prostaglandins and kallikrein (an imbalance 
in kinin-kallikrein equilibrium). 
 
 
Intrarenal vasodilators  Intrarenal vasoconstrictors 
- Prostacyclin  - Angiotensin II 
- Prostaglandin E2  - Norepinephrine 
- Nitric Oxid  - Neuropeptide Z 
- Natriuretic atrial peptide  - Endothelin I 
- Kinin-kallikrein system  - Adenosine 
  - A2 Thromboxane 
- Cysteinyl Leukotriene 
- F2 Isoprostane 
The result is a formidable renal arterial 
vasoconstriction with an extreme ischemia, especially in 
the cortical area and with HRS. 
HRS may also (rarely) develop in other liver 
diseases such as alcoholic hepatitis or in acute liver 
failure [5]. 
The three clinical syndromes (dilutional 
hyponatremia, ascites and HRS) are different 
manifestations of the same pathogenetic axis: PHT- NO-↓ 
AEV→↑RAAS and ↑vasopressin,  ↑Sy (Figure 1). The 
three clinical syndromes are the manifestations of a 
continuous clinical spectrum, the extreme of which is the 
hepatorenal syndrome [5]. These clinical syndromes may 
present as a single syndrome (ascites), in association 
with two of them (ascites and HRS, ascites and 
hyponatraemia) or all three together (HRS, ascites, 
hyponatremia). 
The therapeutic consequence of the above 
mentioned mechanisms is the necessity to maintain the 
EAV by i.v. infusion of albumin when= 9l of ascitic fluid is 
removed by paracenthesis and also i.v. albumin in 
spontaneous bacterial peritonitis, and the association of  
i.v. albumin and vasoconstrictors in type I HRS [3,5,8]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Vasoactive intrarenal substances in HRS [5]. 
 
  Fig. 1 Clinical consequences of renal involvement in PHT 
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